Monday, 20 May 2019

You are here

Increased Risk of Depression and Anxiety in Rheumatoid Arthritis

Canadian researchers have analyzed population data and shown that the incidence and prevalence of depression, anxiety  and bipolar disorders are elevated in the rheumatoid arthritis (RA) patients compared to a matched population.

Estimates on the prevalence of depression and anxiety in RA patients vary widely in the literature. Thus, investigators analyzed population‐based administrative health data from Manitoba, Canada, to identify RA patients and a 5:1 matched control population to estimate the incidence and prevalence of depression, anxiety disorder, bipolar disorder, and schizophrenia. 

Among 10,206 incident cases of RA and 50,960 matched individuals, adjusted incidence rates were reported:

  • Depression: was higher in the RA patients (incidence rate ratio [IRR] 1.46 [95% confidence interval (95% CI) 1.35–1.58]). The lifetime and annual period prevalence of depression was also higher in RA.
  • Anxiety: was higher in RA patients (IRR 1.24 [95% CI 1.15–1.34]). The lifetime and annual period prevalence of anxiety was also higher in RA 
  • Bipolar disorder was also higher (IRR 1.21 [95% CI 1.00–1.47]).
  • Not significant: the frequency of schizophrenia did not differ between groups (IRR 0.96 [95% CI 0.61–1.50]).

The risks of depression, anxiety disorder, and bipolar disorder have not changed over time, despite substantial changes in the clinical management of RA over the 20‐year study period.

Clinicians should be aware that women and those of lower socioeconomic status are at particularly increased risk of these disorders.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioids, SSRIs and Steroids Increase Fracture Risk in RA

Analysis of a large US observational rheumatoid arthritis (RA) patients finds that opioids, SSRIs and glucocorticoids were associated with increased risk of fracture in RA, whereas statins and TNFi had a decreased vertebral fracture risk.

Denosumab Protects Against RA Erosions

Combining denosumab (Prolia) with a conventional disease-modifying antirheumatic drug (DMARD) such as methotrexate showed promise for slowing radiographic damage in rheumatoid arthritis (RA), a manufacturer-sponsored phase III trial called DESIRABLE found.

New ACR/AF Guidelines on JIA Polyarthritis and Uveitis

The American College of Rheumatology (ACR) and the Arthritis Foundation (AF) have released two guidelines on management of juvenile idiopathic arthritis (JIA). The first addresses the treatement of non-systemic polyarthritis, sacroilitis and enthesitis; and the second focuses on JIA associated uveitis - screening, monitoring and treatment.

Shorter Treatment Succeeds in Septic Arthritis

Two weeks of antibiotic therapy was as effective as 4 weeks for septic arthritis, a prospective single-center study found.

Among 77 patients randomized to a 4-week course of therapy following surgical drainage for native joint bacterial arthritis, the rate of complete microbiological remission after at least 2 months of follow-up was 97%, according to Ilker Uçkay, MD, of Uniklinik Balgrist in Zurich, Switzerland, and colleagues.

Targeting GM-CSF Works in Rheumatoid Arthritis

Namilumab, a monoclonal antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand, showed promise as a treatment for rheumatoid arthritis (RA) in a phase II study.